Elequin Capital’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
Elequin Capital's TVTX Position: Q3 2026 in Review
Elequin Capital sold out of Travere Therapeutics (TVTX) in Q3 2026, closing a stake of 16 shares — an estimated $909 sold.
Elequin Capital first reported a position in TVTX in Q1 2022 and held it in 12 quarters. The position peaked at $149K in Q4 2022. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- Elequin Capital reported no remaining Travere Therapeutics position as of Q3 2026 after selling out during the quarter.
- Elequin Capital sold 16 Travere Therapeutics shares in Q3 2026, an estimated $909.
- Elequin Capital first reported a position in Travere Therapeutics in Q1 2022 and held it in 12 quarters.
- Elequin Capital's Travere Therapeutics position peaked at $149K in Q4 2022.
- 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on Elequin Capital's 13F filing for Q3 2026, filed 13 Nov 2026.